Transgenic Group Inc. (TYO:2342)
178.00
-4.00 (-2.20%)
Nov 18, 2026, 10:47 AM JST
Transgenic Group Revenue
Transgenic Group had revenue of 3.41B JPY in the quarter ending September 30, 2026, with 12.65% growth. This brings the company's total for the last twelve months to 14.02B, up 8.52% year-over-year. In the fiscal year ending March 31, 2026, Transgenic Group had annual revenue of 13.17B with 1.30% growth. That makes Transgenic Group the 23,734th largest company in the world by revenue and 2,546th in Japan.
Revenue (ttm)
14.02B
Revenue Growth
+8.52%
P/S Ratio
0.22
Revenue / Employee
61.76M
Employees
227
Market Cap
2.96B
Revenue by Segment
- Investment and Consulting Business 10.92B 82.9%
- Drug Discovery Support Business 2.26B 17.1%
Fiscal year ended Mar 31, 2026 See the full Transgenic Group breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | 13.17B | 169.00M | 1.30% |
| Mar 31, 2025 | 13.01B | -78.00M | -0.60% |
| Mar 31, 2024 | 13.08B | 1.65B | 14.47% |
| Mar 31, 2023 | 11.43B | -1.15B | -9.12% |
| Mar 31, 2022 | 12.58B | 1.53B | 13.85% |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Kohjin Bio | 4.38B |
| Human Metabolome Technologies | 1.48B |
| MEDINET | 998.00M |
| PRISM BioLab Co.,LTD | 737.27M |
| SUSMED,Inc. | 679.00M |
| Kringle Pharma | 442.00M |
| D. Western Therapeutics Institute | 140.90M |
| Ribomic | 19.00M |